Collectively, we here show that rational drug targeting of specific resistance mechanisms—i.e., the mevalonate pathway in TP53-mutant AML cells or the Wnt pathway in CAR T-cells engaging them—can completely rescue TP53-dependent resistance of AML cells to CAR T-cell killing in vitro. This evidence concerns the gene TP53 and acute myeloid leukemia.